CN107048356A - One group of ubiquinone suitable for cardiac rehabilitation phase crowd's cardioprotection10Nutrition companion's composition - Google Patents
One group of ubiquinone suitable for cardiac rehabilitation phase crowd's cardioprotection10Nutrition companion's composition Download PDFInfo
- Publication number
- CN107048356A CN107048356A CN201610184057.0A CN201610184057A CN107048356A CN 107048356 A CN107048356 A CN 107048356A CN 201610184057 A CN201610184057 A CN 201610184057A CN 107048356 A CN107048356 A CN 107048356A
- Authority
- CN
- China
- Prior art keywords
- gram
- vitamin
- ubiquinone
- companion
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 62
- 238000002554 cardiac rehabilitation Methods 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims abstract description 14
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title claims abstract description 13
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 229940035936 ubiquinone Drugs 0.000 title claims abstract description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 80
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 44
- 229960003080 taurine Drugs 0.000 claims abstract description 40
- 229960003624 creatine Drugs 0.000 claims abstract description 22
- 239000006046 creatine Substances 0.000 claims abstract description 22
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 21
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 21
- 230000005961 cardioprotection Effects 0.000 claims abstract description 10
- 230000035764 nutrition Effects 0.000 claims abstract description 10
- 235000016709 nutrition Nutrition 0.000 claims abstract description 10
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical group [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims abstract 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 239000011727 vitamin B9 Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000011715 vitamin B12 Substances 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 5
- 229960000367 inositol Drugs 0.000 claims description 5
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 5
- 239000004378 Glycyrrhizin Substances 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 4
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 3
- 230000035622 drinking Effects 0.000 claims description 2
- 239000003651 drinking water Substances 0.000 claims description 2
- 235000020188 drinking water Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 abstract description 38
- 210000002216 heart Anatomy 0.000 abstract description 38
- 230000001976 improved effect Effects 0.000 abstract description 8
- 230000003130 cardiopathic effect Effects 0.000 abstract description 7
- 208000019622 heart disease Diseases 0.000 abstract description 7
- 208000034657 Convalescence Diseases 0.000 abstract description 6
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 230000001934 delay Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 62
- 229950007002 phosphocreatine Drugs 0.000 description 31
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 25
- 210000004165 myocardium Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 16
- 230000003834 intracellular effect Effects 0.000 description 15
- 230000006378 damage Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 239000003963 antioxidant agent Substances 0.000 description 11
- 210000004413 cardiac myocyte Anatomy 0.000 description 11
- 230000003078 antioxidant effect Effects 0.000 description 10
- 210000000170 cell membrane Anatomy 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000000747 cardiac effect Effects 0.000 description 8
- 230000002438 mitochondrial effect Effects 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- -1 NADH ubiquinones Chemical class 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 230000004224 protection Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 5
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 210000001700 mitochondrial membrane Anatomy 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 101710088194 Dehydrogenase Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 230000002407 ATP formation Effects 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000001964 calcium overload Effects 0.000 description 3
- 239000000496 cardiotonic agent Substances 0.000 description 3
- 229940110767 coenzyme Q10 Drugs 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000010627 oxidative phosphorylation Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005189 cardiac health Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000027721 electron transport chain Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000008125 glucin Substances 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- BPMFZUMJYQTVII-UHFFFAOYSA-N guanidinoacetic acid Chemical compound NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003680 myocardial damage Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000037050 permeability transition Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- FYGHPRWSAALUHI-UHFFFAOYSA-N 3,7-dihydropurine-2,6-dione;7h-purine Chemical compound C1=NC=C2NC=NC2=N1.O=C1NC(=O)NC2=C1NC=N2 FYGHPRWSAALUHI-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102000007272 Apoptosis Inducing Factor Human genes 0.000 description 1
- 108010033604 Apoptosis Inducing Factor Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- YPZRHBJKEMOYQH-UYBVJOGSSA-N FADH2 Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000004668 Mitochondrial Form Creatine Kinase Human genes 0.000 description 1
- 108010003865 Mitochondrial Form Creatine Kinase Proteins 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 108091005975 Myofilaments Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001201 calcium accumulation Effects 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000006706 cellular oxygen consumption Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000009091 contractile dysfunction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- IZFHEQBZOYJLPK-UHFFFAOYSA-N dihydrolipoic acid Chemical compound OC(=O)CCCCC(S)CCS IZFHEQBZOYJLPK-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 210000004536 heart mitochondria Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
- 230000006686 mitochondrial oxygen consumption Effects 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 108010028584 nucleotidase Proteins 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention relates to the ubiquinone that one group is applied to cardiac rehabilitation phase crowd's cardioprotection10Contain the taurine in taurine, three kinds of compositions of lipoic acid and creatine, formula in nutrition companion's composition, said composition formula, lipoic acid and creatine are constituted by a certain percentage, with ubiquinone10Take simultaneously, ubiquinone can be promoted10Cardioprotection, promotes cardiac rehabilitation, delays cardiopathic generation and development, it is ensured that the quality of life of cardiac rehabilitation phase crowd.Ubiquinone10Different taking doses can be designed according to cardiac rehabilitation phase crowd, this product is used as ubiquinone10Companion, take simultaneously, also can be ubiquinone10It is added to simultaneously in formula, facilitates user to apply.This product is to the elderly because of coronary artery disease, and the convalescence crowd after heart failure takes a turn for the better through treatment caused by the reason such as hypertension is particularly suitable, can advantageously promote the rehabilitation of heart, and cardioprotection, recurring again for prevention heart disease is improved the quality of living.
Description
Technical field
The present invention relates to Co-Q10 nutrition companion's composition that one group is applied to cardiac rehabilitation phase crowd's cardioprotection,
Said composition is to the elderly because of coronary artery disease, hypertension, cardiomyopathy, aging, valvulopathy and Congenital Heart
Cardiac insufficiency caused by the reasons such as disease, the convalescence crowd after heart failure takes a turn for the better through treatment is particularly suitable, can be preferably
Promote the rehabilitation of heart, cardioprotection, recurring again for prevention heart disease belongs to the technical field of medical health care product.
Background technology
Heart is a most important organ in human body, and major function is to provide pressure, blood operation to body each
Part, the mission for completing conveying blood.Research shows, time of the heart less than one minute, just blood can be sent into whole body
Each cell, so circulates a whole day, and the oxygen-rich blood that heart will be about bounce 100,000 time, 2,000 gallons will be
Run quickly on 60,000 miles of blood vessel highway multiple, complete the challenge to each cell delivery blood of body.It is right
In the muscle of fist size, this can't but be an ass work and moves.With advancing age, motion and the consumption of muscle power,
The pressure of environment and spirit, the damage of disease etc., the function of heart can be all influenceed, causes cardiac insufficiency, heart failure.At present
The heart failure of definition refer to the pump blood (contractile dysfunction) for causing heart because heart lacks enough energy supply and/
Or diastolic dysfunction (Diastolic Heart failure), cause body a series of uncomfortable cardiac symptoms and sign occur.Cause the heart
The reason for force failure, is more, and most commonly seen is coronary artery disease, hypertension, cardiomyopathy, aging, valvulopathy and elder generation
Nature heart disease.The data display of American Heart Association (AHA) statistics, 5,100,000 people are had in the U.S. with heart failure, and
The whole world has 23,000,000 people to be diagnosed as heart failure.The morbidity and mortality of heart failure also increase therewith with advancing age
Plus, and it is reported that death accounts for 1/9th in U.S.'s heart failure.In addition, heart failure be the elderly's hospitalization and
One of disabled most common reason.Although there is the drug therapy heart failure of significant improvement, it is continued above per annual death rate
10%, it is serious in the case of reach 20% to 50%.The old age fifties 3 years case fatality rate of heart failure are more than 80%, wherein most 2
It is dead in year.Nearest data shows that man, 2 years case fatality rate of female old aged people heart failure are respectively 37% and 38%, is respectively within 6 years 82% He
61%.With the improvement of remedy measures, prognosis makes moderate progress, but old heart failure case fatality rate people is higher than middle-young patients 4~8 times,
More than 85 years old males are compared with 75~84 years old high 3 times, and women is high 4 times, and People prognosis is worst.Anti heart failure treatment will not extend chronic
The life cycle of patient in serious heart failure, in order to protect heart failure in convalescent heart, promote the rehabilitation of heart, improve heart
The life quality of patient, one group of this Project design is applied to the Co-Q10 nutrition of cardiac rehabilitation phase crowd's shield heart effect
Companion's composition, is these crowd's cardioprotections, improves life quality, and extension life cycle provides a kind of good health food.
Co-Q10 prolonged application has been found to that the symptom of heart failure can be improved, and reduces main adverse cardiac events
And the death rate, there is good tolerance and security.Co-Q10 is a kind of fat-soluble quinones chemical combination being widely present in human body
Thing, also known as ubiquinone, it is in the content highest of heart, and it is as a kind of important confactor, in mitochondrial oxidative phosphorylation
Middle formation ATP plays a crucial role.In electron transport chain (ETC), its mediated electron is from complex 1 (NADH ubiquinones reductase)
Complex 3 (CYB C1 is combined) is transferred to, and complex 3 is delivered to from complex 2 (succinate dehydrogenase).In addition,
Co-Q10 has direct antioxidation, prevents film from aoxidizing and lipid peroxidation, stable LDL particles, promotes to reclaim α fertilities
Phenol, so as to protect cardiovascular health.Co-Q10 content highest in cardiac muscle, Co-Q10 can stablize the upper Ca-dependent of cardiac muscle and lead to
The synthesis in road, effectively enhancing ATP.Clinical observation has proven to congestive heart failure (CHF) and heart muscle coenzyme Q10 reduction is close
Correlation, is the key factor of the occurrence and development of heart failure.Heart muscle coenzyme Q10 levels are related to the order of severity of symptoms of heart failure
Connection, in addition, Co-Q10 passes through its antioxidation, it is possible to reduce oxidative stress, it is unfavorable that influence left ventricular ejection fraction is produced
Factor, and change disease outcome.Recent years abroad scholar is in a series of long-term, polycentric use Co-Q10 auxiliary treatment heart failures
In the check experiment exhausted, it was demonstrated that Co-Q10 can be improved such as LVEF, the function such as stroke output and cardiac output ginseng really
Number, and have no side effect.But although these results are confirmed by subsequent statistical analysis, but in severe heart failure patients, or
In the case where Vel-Tyr-Pro-Trp-Thr-Gln-Arg-Phe is treated, benefited amplitude is not also particularly significant.But, Co-Q10 is used alone in heart
After disease, particularly heart failure therapy, patient symptom improves, the convalescence after the discharge that takes a turn for the better, and continues to supplement Co-Q10, is
No to promote cardiac rehabilitation, delay heart failure occurs again, and there is presently no research report, this project team passes through to hundreds of
The informal clinical observation of the various cardiac rehabilitation phase patients of example, it is found that they take Co-Q10 in convalescence, to heart disease
Symptom improve significantly, illustrate Co-Q10 have promote heart rehabilitation, the important shield heart thing for quality of making the life better
Matter.
This project is inventors noted that in the generation and development of heart failure, while heart Co-Q10 is reduced, sulphur
The material relevant with cardiac energy generation such as octanoic acid, taurine and creatine is also reduced to some extent, these and heart failure
Relevant material is supplemented as the shield heart companion of Co-Q10, can be remarkably reinforced shield heart effect of Co-Q10, be strengthened it
Anti-fatigue ability, antiinflammatory action, anti-aging effects have a very important role to cardiopathic treatment and rehabilitation.
Taurine be it is a kind of be content most abundant free amino acid in body, it is unable to conjugated protein, animal body
Interior taurine almost all is widely present in the tissue, intracellular of all animals in a free form.Brain, ovary, uterus,
Heart, liver, kidney, bone slit, rich content in muscle, blood.Taurine is content highest in cardiac muscle of mammal tissue
A kind of amino acid, 20-70mmol/L can be reached by accounting for taurine concentration in the 50% of all free amino acids, cardiac muscle cell,
The ratio between taurine concentration is 200: 1 in cardiac muscle cell and in blood plasma.Taurine has obvious guarantor for heart tissue and cell
Shield is acted on, and document report taurine is mainly damaged by suppressing Apoptosis, stabilizing cell membrane, anti peroxidation of lipid, removes oxygen
Free radical, regulation Premeabilisation of cells pressure, the mechanism such as intracellular calcium homeostasis is maintained, play and protect myocardial damage caused by ischemic, prevent
On the one hand taurine in the effect of stop pulse atherosclerosis and regulation blood pressure, human body derives from being endogenously synthesized for itself, one
Aspect is supplied from exogenous meals.Myocardial damage caused by research discovery a variety of causes may be such that cardiac muscle cell's taurine
Release, causes myocardium, intracellular content of taurine reduction and content of taurine is significantly raised in blood plasma.In the pathology shape of hypertension
Under state, the content of taurine in cardiac muscle cell is also decreased obviously.Exogenous supplementation of taurine can significantly reduce Acute myocardial and lack
The necrosis of cardiac muscular tissue caused by blood and the tune of cardiac muscle cell are died, and its moderate resistance adjusts the expression for dying GAP-associated protein GAP Bcl-2 significantly raised,
And pro apoptotic protein Bax expression is decreased obviously, Zuo Xin Shi Shou Shrink and end-diastolic internal diameter are obviously reduced, left ventricular ejection fraction and
Left ventricle shortens fraction and substantially increased, hence it is evident that improve the situation of the decrease of heart function caused by acute ischemia.In vitro cell experiment
It was found that taurine can weaken cardiomyocyte proliferation caused by response to oxidative stress caused by sugar deficiency injury and reversible sugar deficiency injury
Reduction.In addition, taurine can adjust the triggering for dying path, reactive oxygen species by adjusting the generation of oxygen radical
(ROS) and MDA (MDA) is the product of oxidative stress and lipid peroxidation injury, research find sugar deficiency injury cause ROS and
MDA produces increase, and taurine can significantly reduce ROS and MDA generation, and taurine further suppress the cardiac muscle of sugar deficiency injury induction
The decline of mitochondrial membrane potential in anoxic.Research is it has also been found that the apoptosis that taurine reduces the ER/SR mediations of sugar deficiency injury induction leads to
Road, intracellular calcium overload can induce ROS generation and further promote endoplasmic reticulum release calcium ion to aggravate intracellular calcium overload,
Promote Apoptosis, the tune that the pretreatment of low dosage taurine can significantly reduce cardiac muscle cell caused by anoxic is died, and is reversed scarce
The reduction of cardiomyocyte proliferation caused by oxygen.Supplementation of taurine can reduce animal blood plasma cholesterol levels, reduce artery athero-
The generation of hardening, taurine also has adjustment effect to blood pressure, and supplementation of taurine can substantially reduce the blood pressure of patient.Taurine is
The important component of myocardium free amino acid, can also pass through calcium electricity caused by suppressing virus replication, suppression virus infection cardiac muscle cell
Stream increase, makes maximum calcium current membrane voltage and outward potassium current infected and reduce tend to be normal, makes cardiac muscle cell's Ca2+ influx
Reduce, there is protection cardiac muscle in vital myocarditis animal model and clinical Patients with Viral Myocarditis, improve clinical symptoms
Deng effect.Co-Q10 plays an important role in human body respiration chain in proton displacement and electron transmission, can be as cell metabolism and thin
Born of the same parents breathe activator, or important antioxidant and nonspecific immunity strengthening agent, oxidative phosphorylation can be promoted to react, and protect
Biofilm structure integrality, with resisting myocardial ischemia, anti-arrhythmia, improves energy metabolism of myocardial, scavenging activated oxygen etc. and makees
With, cardiac output can be increased, peripheral vascular resistance is reduced, the use in conjunction together with taurine is myocardium to protection, the promotion damage heart
The recovery of myocyte, can produce preferably joint curative effect, the present invention using taurine as Co-Q10 shield heart nutrition companion, just
The protection cardiac muscle of Co-Q10 can be given full play to and promote the effect of cardiac rehabilitation, be the essential shield heart of human heart health
Nutrient.Taurine can be equipped with, Dan Ru as the reinforcing replenishers of Co-Q10 cardioprotection in 50~100: 1 ratio
Other cardiac stimulant nutrients compatibility together, this ratio can also be reduced.
Lipoic acid belongs to vitamine B group compound, and s is taken off in pyruvic dehydrogenase, ketoglurate dehydrogenase, aminocaproic acid
Worked in the multienzyme complexs such as carboxylic acid as coenzyme.Lipoic acid is the confactor of pyruvic dehydrogenase, and it promotes pyruvic acid
Be changed into acetyl coenzyme A generation reduced flavin adenine dinucleotide (FADH), be participate in tricarboxylic acid cycle during can not
The material lacked.Lipoic acid or a kind of metabolic antioxidant, the dihydro sulphur that reduced form can be converted into vivo are pungent
The lipoic acid of sour (DHLA), oxidized form and reduced form all has very strong inoxidizability, and they act synergistically in vivo, are known
Effect most strong one kind in natural inhibitor.Lipoic acid is indispensable confactor during internal ATP is produced, and it joins
With tricarboxylic acid cycle, a variety of free radicals can be effective against, and can adjust other antioxidants, body is played a protective role.
Lipoic acid strengthens the oxidation resistance of body, by improving internal main antioxidant enzyme superoxide dismutase (SOD), peroxidating
The activity of the sweet skin peroxidase (GSH-PX) of hydrogen enzyme (CAT), paddy skin and the sweet fabk polypeptide of paddy skin (GR) is anti-oxidant to play its
Function, plays the function of its Scavenger of ROS.Lipoic acid can reduce the oxidative stress of cell liquid, strengthen the anti-oxidant energy of cell
Power, so as to mitigate mitochondrial oxidative stress, the ability with very strong removing free radical is mitochondria resistance peroxidization
Produce the optimal antioxidant of free radical.It can mitigate anti-oxidant in the oxidative stress degree of myocardial ischemia-reperfusion, reinforcement
The activity of enzyme, increase mitochondrial membrane potential and cell oxygen consumption, reduce the effect of active oxygen generation and maintain cell biological film
The integrality of function.We have discovered that, lipoic acid and Co-Q10 use in conjunction, it removes the effect of free radical, reduces cell
Consumption to ATP, has positive effect, while internal main antioxidant enzyme super oxygen can also be improved to reducing mitochondrial oxygen consumption
The activity of thing mutase (SOD), the effect with stabilizing cell membrane maintains the integrality of cell mitochondrial structure, mitigates cell
Oedema and mitochondrial dissolving, prevent the arrangement disorder of membranolysis and muscle fibre.To heart failure caused by a variety of causes
Exhausting has good protective effect, and to the convalescence after heart failure control, helpful cardiac rehabilitation prevents or delays heart failure
Occur again with obvious health-care effect.Lipoic acid, can be by 50~100 as the reinforcing replenishers of Co-Q10 cardioprotection:
1 ratio is equipped with, and singly such as other cardiac stimulant nutrients together compatibility, this ratio can also be reduced.
Creatine is conducive to the conversion of mitochondria energy as a kind of internal spontaneous nitrogenous organic acid, stable ATP's
Synthesis, adjusts ATP and ADP ratio, the function of ATP enzyme is not over-constrained.Creatine is used as a kind of indirect antioxidant
Play an important roll in terms of mitochondrial permeability transhipment is prevented.In vivo, creatine is anti-with arginine by glycine in kidney
Glycocyamine should be formed, is then formed in liver through methylating, creatine forms phosphocreatine after being phosphorylated in each tissue,
Phosphocreatine is to participate in one of important substance of cellular energy metabolism, is also the important energy supply source of cell, is Adenosine triphosphate
Glycosides (ATP) supplements energy, and ATP is topmost energy source in any cellular process.Phosphocreatine is primarily present in the heart
Contour the intracellular of organ that consume energy of flesh, skeletal muscle, brain, its main Physiological Function is：1. it is these highly energy-consuming cell intracellulars
" buffer " of ATP constant concentrations, these organs or cell will consume a large amount of ATP during vital movement, consume ATP benefit
Filling will lean on intracellular phosphocreatine to convert；2. it is the energy of these cells from generating unit to the load of consumption position transfer
Body.The mitochondrial creatine kinase of highly energy-consuming cell is produced mitochondrial matrix by the couple with adenyltransferase
ATP is converted into phosphocreatine, under the catalysis of endochylema creatine kinase, phosphocreatine by the energy-rich phosphate group from ATP most
Power consumption position (such as muscle fibre and ionic pump) is transferred to eventually, enables ATP enzyme catabolite-adenosine diphosphate (ADP) of there phosphorus again
Acidifying.Phosphocreatine plays a part of carrier in the transfer process of ATP energy-rich phosphate groups.Phosphocreatine is to myocardial cell membrane
Have important protective effect, when cardiac muscle is damaged by hypoxic-ischemic, there is coupling in mitochondrial respiratory chain electron transmission, proton pump
Join obstacle, O2Reduction disorder produces O2And then change generation OH.It is yellow and a large amount of ATP degradeds produce hypoxanthine, xanthine
Purine dehydrogenase is transformed into oxidizing ferment, has a large amount of oxygen molecules to enter during Reperfu- sion and produces a large amount of O2, in the presence of transition metal
It is transformed into OH.A large amount of OH can produce peroxidation to the membrane phospholipid on myocardial cell membrane, cause basement membrane portion to lack,
Destruction of plasma membrane, damage be rapidly spread to whole cell make muscle fibril structure destroy, occur significant shrinkage band or myofilament fracture, it is molten
Solution.In addition, OH also results in the contracture of calcium accumulation in the cell and cardiac muscle.Phosphocreatine being capable of inhibition of phospholipase A2Enzyme is anti-
Should, by phospholipase A2The suppression of activity, so as to suppress the rise of hemolytic phosphoglycerol in membrane phospholipid.Not only protect flesh
The integrality of fine membrane structure, and add the stability of ischemic myocardium potential change.Hemolytic phosphoglycerol has been found to
Cause the phospholipid metabolism intermediate product of arrhythmia cordis, therefore phosphocreatine is then that phosphocreatine has the anti-heart to the suppression that it is produced
Restrain the pharmacological basis of not normal effect.Phosphocreatine can increase the stability of ischemic myocardium potential change, also with phosphocreatine molecule
This body structure is related：One end of phosphocreatine molecule is negatively charged phosphate group, can be with band in cell membrane membrane phospholipid molecule
The NR of positive charge3+Group is combined closely, and this phosphocreatine molecule other end carboxylic group is also negatively charged, with adjacent phospholipid point
The NR of subband positive charge3+Group produces same combine closely.Phosphocreatine molecule is combined closely with adjacent membranes phospholipid molecule
Cause the exposure reduction of membrane phospholipid molecular surface charge, so that the phospholipid molecule on film is stable.In addition, phosphocreatine is by for Ca
Pump energizes and suppressed the anaerobic metabolism of sugar to reduce intracellular Ca2+、H+Aggregation, reduce OH generation, maintain cell
The stability of film and cardiac muscle.Phosphocreatine can suppress 5 ' on film-activity of nucleotidase, pass through the suppression to the enzyme, Ke Yiwen
Fixed intracellular determination of adenosine phosphates in mouse, the progress being metabolized to intracellular energy creates condition.In addition, phosphocreatine molecule is demonstrate,proved
It is real to enter cell through cell membrane, and its diffusion coefficient in the cell is all bigger than ATP and adenosine diphosphate (ADP), and this just serves as reasons
The condition of creating is operationalized again in the abnormal energetic supersession reaction " chain " caused by cell membrane breakage.Phosphocreatine is to line
Plastochondria, which also has, has a kind of Proteinaceous duct-permeability transition pore at important protective effect, the inside and outside membrane junction of mitochondria,
Ca2+Excess load, oxidative stress etc., which are stimulated, can cause permeability transition pore to open, and cause mitochondrial membrane potential disintegration, breathing
Chain is broken, and energy metabolism impairment causes cell death.Permeability transition pore open can also result in cromoci and apoptosis induction because
Son release, activates apoptosis core enzyme caspase, so that regulating cell apoptosis.Phosphocreatine energy partial reduction oxidative stress status
The decline of lower myocardial mitochondria film potential, maintains Mitochondrial Membrane Structure complete and normal oxidation phosphorylation function, and suppress film
The opening in penetrating change duct, reduces the generation of the injurious factors such as cromoci, apoptosis inducing factor, so as to reduce cardiac muscle
Apoptosis.Intracellular sufficient ATP synthesis is the basis of myocardium excitation-excitation-contraction coupling, and phosphocreatine is ATP storage and turned
Fortune form, intracellular energy transmission is realized in the presence of creatine kinase isozyme by " phosphocreatine shuttle ".Cardiac muscle
During generation ischemic, aerobic metabolism obstacle, intracellular ATP exhausts, phosphocreatine changes into ATP to maintain cellular energy generation in time
Thank.Because phosphocreatine directly can enter intracellular by cell membrane, and ATP molecular volumes are big, are difficult to pass through cell membrane, therefore
It is more superior in terms of energy metabolism of myocardial is improved.In cardiac muscle cell certain density phosphocreatine be maintain normal heart function must
Condition is wanted, phosphocreatine level in normal myocardium compared with being decreased obviously in the cardiac muscle of heart failure patient, and its decreasing ratio is obvious
Higher than ATP, and decline degree and the order of severity of heart failure are linear, improve the intramyocardial phosphoric acid of heart failure patient
Creatine content can increase cardiac output and Left Ventricular Ejection Fraction, also can obviously reduce left ventricular end diastolic presssure and increase after Reperfu- sion
Coronary flow.Phosphocreatine is applied to find that it can obviously reduce left room and shrinks end after heart failure patient by clinical research
With end-diastolic diameter, LVEF is improved, cardiac function is improved, in addition, newest research shows, phosphocreatine can also relax
Coronary artery is opened, increases coronary flow, improves myocardial oxygen.Illustrate that phosphocreatine can be improved by number of mechanisms
The energetic supersession state of heart, saves the excitability of cardiac muscle, conductibility and its shrinkage, reduces the hair of arrhythmia cordis
It is raw, preferably maintain cardiac function.
CoQ10 has the function of promoting oxidative phosphorylation reaction and protection biofilm structure integrality.The main function of Co-Q10
It is to transmit electronics between mitochondrial inner membrane composite I and III, II and III.Creatine and Co-Q10 therapeutic alliance can increase
The synthesis of phosphatide and recycling, reduce the release of central nervous system phosphatide, the protective effect with heart and nerve, study table
Bright two medicine share can (1) stable Mitochondria function, improve energetic supersession, improve mitochondrial complex I activity, subtract
The generation of few free radical, to antioxidant stress injury；(2) stable mitochondrial permeability transhipment (MPT) duct, reduces its penetrating
Property, suppress Apoptosis.Prevent CoQ10 from respiratory chain depigmentation, oxidative phosphorylation are obstructed, mitochondrial membrane potential is lost, oxidation is answered
MPT permeabilities increase caused by the factors such as sharp, calcium overload；(3) the mutual conversion of creatine and phosphocreatine is conducive to mitochondria energy
The conversion of amount, stable ATP synthesis, adjusts ATP and ADP ratio, the function of ATP enzyme is not over-constrained；(4) to antioxygen
Change stress to membrane phospholipid destruction, accelerate phosphatide to synthesize again.Creatine, can as the reinforcing replenishers of Co-Q10 cardioprotection
To be equipped with 50~100: 1 ratio, singly such as other cardiac stimulant nutrients together compatibility, this ratio can also be reduced.
We have discovered that, the patient of heart failure is caused to a variety of causes, after hospital is treated, is particularly existed
Leave hospital during rehabilitation, taking Co-Q10 has preferable guaranteeing role to cardiopathic rehabilitation, but is taking the same of Co-Q10
When, add containing taurine, the Co-Q10 shield heart companion of lipoic acid and creatine, there is more preferable auxiliary to cardiopathic rehabilitation
Health-care effect, we are taurine is contained, and the composition constituted based on lipoic acid and creatine is prepared into the promotion cardiac rehabilitation phase
The Co-Q10 nutrition companion of crowd's shield heart effect, this nutrition companion includes beverage, tablet, electuary, oral liquid, capsule.We
Proved by zoopery, while giving Co-Q10, these nutrition companion is added, to causing mouse heart to damage by adriamycin
Cardiac toxic caused by wound, is the optimal health treatment of cardiac rehabilitation phase crowd's shield heart with good rehabilitative action.
The content of the invention
The present invention proposes one group of Co-Q10 nutrition companion for being applied to cardiac rehabilitation phase crowd's cardioprotection and combined
Thing, it is characterized in that contain taurine in said composition formula, three kinds of compositions of lipoic acid and creatine, the taurine in formula, sulphur is pungent
Acid and the ratio of creatine three are：1∶1∶2.The formula can contain Co-Q10, and Co-Q10 per unit composition is (each taking agent
Amount) it is 10mg~50mg, Co-Q10 can also not be contained, as the companion for taking Co-Q10, that is, when taking Co-Q10, together
When take this Co-Q10 companion.The consumption of Co-Q10 can be taken according to the weight of the state of an illness and the suggestion of doctor, when taking
Co-Q10 companion is added, more preferable facilitation can be played to cardiopathic rehabilitation, our research is also confirmed, these coenzyme
Q10 Mated clothes do not result in adverse reaction with heavy dose yet, are a safe and reliable health products.
Embodiment：
The following is the specific embodiment of the present invention, technical scheme is done and is further described, but it is of the invention
Protection domain be not limited to these embodiments, every change or equivalent substitute without departing substantially from present inventive concept is included in this hair
Within bright protection domain.
Embodiment one
Ubiquinone10Shield heart companion (beverage)：Its formula is：1~10 gram of taurine, 1~10 gram of lipoic acid, creatine 1~20
Gram, 0.3~1 gram of vitamin C, vitamin B11~10 milligram, vitamin B21~10 milligram, vitamin B61~10 milligram,
Vitamin B91~10 milligram, vitamin B121~10 milligram, 0.2~1.2 gram of glycyrrhizin, 1.5~10 grams of citric acid, paddy ammonia
0.1~0.6 gram of acid amides, 0.1~0.6 gram of inositol, 0.1~0.6 gram of potassium chloride, 0.1~0.6 gram of sodium chloride, the formula is with drinking
1 liter of preparation of water.The beverage can be as the companion for taking Co-Q10, when taking Co-Q10, while being sent with companion's beverage
Clothes.
Above-mentioned drink formula, its optimum formula is：3 grams of taurine, 3 grams of lipoic acid, 6 grams of creatine, 0.5 gram of vitamin C,
Vitamin B18 milligrams, vitamin B26 milligrams, vitamin B66 milligrams, vitamin B96 milligrams, vitamin B12It is 1 milligram, sweet
Careless 0.6 gram of glucin, 2 grams of citric acid, 0.3 gram of glutamine, 0.3 gram of inositol, 0.3 gram of potassium chloride, 1.35 grams of sodium chloride, the formula
With 1 liter of preparation of drinking water.
Embodiment two
Ubiquinone10Shield heart companion (electuary)：Its formula is：1~10 gram of taurine, 1~10 gram of lipoic acid, creatine 1~20
Gram, 0.3~1 gram of vitamin C, vitamin B11~10 milligram, vitamin B21~10 milligram, vitamin B61~10 milligram,
Vitamin B91~10 milligram, vitamin B121~10 milligram, 0.2~1.2 gram of glycyrrhizin, 1.5~10 grams of citric acid, paddy ammonia
0.1~0.6 gram of acid amides, 0.1~0.6 gram of inositol, 0.1~0.6 gram of potassium chloride, 0.1~0.6 gram of sodium chloride, should match somebody with somebody can be divided into 4
~5 bags, facing the used time, often bag boiling water 200~250 is taken after mixing it with water.When taking Co-Q10, while being taken with companion's beverage.Should
Electuary raw material powder can also add water miscible enzyme Q10 and pack together.
Above-mentioned electuary prescription, its optimum formula is：3 grams of taurine, 3 grams of lipoic acid, 6 grams of creatine, 0.5 gram of vitamin C,
Vitamin B18 milligrams, vitamin B26 milligrams, vitamin B66 milligrams, vitamin B96 milligrams, vitamin B12It is 1 milligram, sweet
Careless 0.6 gram of glucin, 2 grams of citric acid, 0.3 gram of glutamine, 0.3 gram of inositol, 0.3 gram of potassium chloride, 1.35 grams of sodium chloride, the formula
4 bags can be divided into, often bag uses 250ml taken with boiled water；Should be with 5 bags can be divided into, often bag uses 200ml taken with boiled water；The formula may be used also
To be divided into 3 bags as needed, the Different Package such as 6 bags is faced the used time and taken after mixing it with water with different amounts of boiling water.The electuary can also be added water-soluble
The Co-Q10 of property is packed together.
Above-mentioned formula, can be made the beverage of different capabilities, oral liquid, electuary, pulvis, granule, tablet, capsule,
For market application.
Research shows that this Co-Q10 shield heart beverage-mate is special in heart disease to heart disease patient caused by a variety of causes
It is not after heart failure hospitalization improvement discharge, to take, used as Co-Q10 shield heart Mated clothes in cardiopathic convalescence,
The rehabilitation of heart can be promoted, mitigate cardiopathic various clinical symptoms, particularly walk, the symptom such as asthma gone upstairs improves
The quality of life of cardiac rehabilitation phase crowd, in the cycle for delaying heart disease to recur, be a kind of to have particularly significant health to cardiac rehabilitation
The shield heart health food of multiple function.
Claims (5)
1. one group of ubiquinone for being applied to cardiac rehabilitation phase crowd's cardioprotection10Nutrition companion's composition, it is characterized in that the combination
Contain taurine, three kinds of compositions of lipoic acid and creatine in composition formula, the ratio of these three compositions is：1∶1∶2.
2. the one group as claimed in claim 1 ubiquinone for being applied to cardiac rehabilitation phase crowd's cardioprotection10Nutrition companion combines
Thing, it is characterized in that the formula of said composition is：1~10 gram of taurine, 1~10 gram of lipoic acid, 2~20 grams of creatine, vitamin C
0.3~1 gram, vitamin B11~10 milligram, vitamin B21~10 milligram, vitamin B61~10 milligram, vitamin B91~10 milli
Gram, vitamin B121~10 milligram, 0.2~1.2 gram of glycyrrhizin, 1.5~10 grams of citric acid, 0.1~0.6 gram of glutamine, flesh
0.1~0.6 gram of alcohol, 0.1~0.6 gram of potassium chloride, 0.1~0.6 gram of sodium chloride, the formula 1 liter of preparation of drinking water.
3. the one group as claimed in claim 1 ubiquinone for being applied to cardiac rehabilitation phase crowd's cardioprotection10Nutrition companion combines
Thing, it is characterized in that the optimum formula of said composition is：3 grams of taurine, 3 grams of lipoic acid, 6 grams of creatine, 0.5 gram of vitamin C, dimension
Raw element B18 milligrams, vitamin B26 milligrams, vitamin B66 milligrams, vitamin B96 milligrams, vitamin B121 milligram, glycyrrhizin
0.6 gram, 2 grams of citric acid, 0.3 gram of glutamine, 0.3 gram of inositol, 0.3 gram of potassium chloride, 1.35 grams of sodium chloride, the formula is with drinking
1 liter of preparation of water.
4. such as claim 1, one group of Co-Q10 nutrition companion suitable for cardiac rehabilitation phase crowd's cardioprotection described in 2,3
The formula of companion's composition, the formula can be directly added into ubiquinone10, addition is 0.1~5 gram every liter.
5. such as claim 1, one group of Co-Q10 nutrition suitable for cardiac rehabilitation phase crowd's cardioprotection described in 2,3,4
Beverage, oral liquid, electuary, pulvis, granule, tablet can be made in the formula of companion's composition, the formula.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610184057.0A CN107048356A (en) | 2016-03-17 | 2016-03-17 | One group of ubiquinone suitable for cardiac rehabilitation phase crowd's cardioprotection10Nutrition companion's composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610184057.0A CN107048356A (en) | 2016-03-17 | 2016-03-17 | One group of ubiquinone suitable for cardiac rehabilitation phase crowd's cardioprotection10Nutrition companion's composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107048356A true CN107048356A (en) | 2017-08-18 |
Family
ID=59616783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610184057.0A Pending CN107048356A (en) | 2016-03-17 | 2016-03-17 | One group of ubiquinone suitable for cardiac rehabilitation phase crowd's cardioprotection10Nutrition companion's composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107048356A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101669938A (en) * | 2008-09-11 | 2010-03-17 | 上海体育科学研究所 | Nutrient composition for eliminating exercise-induced fatigue |
| CN104784443A (en) * | 2015-05-04 | 2015-07-22 | 威海御膳坊生物科技有限公司 | Coenzyme Q10 compound preparation |
-
2016
- 2016-03-17 CN CN201610184057.0A patent/CN107048356A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101669938A (en) * | 2008-09-11 | 2010-03-17 | 上海体育科学研究所 | Nutrient composition for eliminating exercise-induced fatigue |
| CN104784443A (en) * | 2015-05-04 | 2015-07-22 | 威海御膳坊生物科技有限公司 | Coenzyme Q10 compound preparation |
Non-Patent Citations (3)
| Title |
|---|
| A.H.恩斯明格等: "《美国《食品和营养百科全书》选辑（4）营养素》", 31 December 1989 * |
| JIROU001: "肌酸的22个常见问题", 《肌肉网（HTTPS://WWW.JIROU.COM/YINGYANG/JISUAN/20140315/7911.HTML）》 * |
| 加百列: "《如何选择营养素》", 30 June 2009 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8389005B2 (en) | Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance | |
| US20070292493A1 (en) | Pharmaceutical composition and method for the transdermal delivery of calcium | |
| EP0969744B1 (en) | Nutritional composition for improvements in cell energetics | |
| CN101248873A (en) | Drinking food product with sight protection function | |
| WO2008054695A2 (en) | Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization | |
| US20050260277A1 (en) | Method and formula for anti-tumor and anti-matastatic effect | |
| Peng et al. | β‐Carotene exhibits antioxidant and anti‐apoptotic properties to prevent ethanol‐induced cytotoxicity in isolated rat hepatocytes | |
| EP2257300B1 (en) | Formulas comprising calcium, magnesium, zinc, and vitamin d3 for the prevention and amelioration of osteoporosis | |
| US20070218126A1 (en) | Compositions and Methods for Reducing Inflammation and Pain Associated with Acidosis | |
| WO2001015745A9 (en) | Method and formula for tumor remission and suppression of cancer | |
| CN110664824B (en) | Nutrition supporting agent and preparation method and application thereof | |
| CN107048356A (en) | One group of ubiquinone suitable for cardiac rehabilitation phase crowd's cardioprotection10Nutrition companion's composition | |
| CN107184598A (en) | A kind of pet heart disease composite tablet | |
| WO2008151520A1 (en) | A use of sodium selenosulfate for supplementing selenium and enhancing the cure effectiveness of chemotherapy agents,and the rapidly preparing method thereof | |
| EP1489925A1 (en) | Composition comprising phosphate | |
| EP4147693A1 (en) | Method for enhancing energy production and metabolism in cells | |
| CN102771794A (en) | Soft capsule made of seabuckthorn oil and vitamins EC | |
| JP2005522485A (en) | Methods for reducing calcified arterial plaque accumulation and cell dysfunction and balancing ionic calcium | |
| CN111838669B (en) | Nano composition for treating and improving vulnerable viscera, preparation method and application | |
| Rathod et al. | Coenzyme Q10 gel in periodontal diseases-a wonderful remedy | |
| CN108433106A (en) | A kind of Oxygen-deficient endurance fructose powder (liquid) composition | |
| AU5778801A (en) | Improvements in effervescent tablet manufacture | |
| KR20120119686A (en) | A functional beverage composition comprising l-arginine, vitamin c, vitamin b complex, vitamin a, vitamin e and potassium iodide as main ingredients | |
| Scheer | CoQio | |
| JP2023062717A (en) | Nmn-containing antiaging composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DD01 | Delivery of document by public notice |
Addressee: GUANGDONG RUNHE BIOTECHNOLOGY CO., LTD. Document name: Notification to Make Rectification |
|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 510800 13, Fengshang building, 10 Fenghuang North Road, Huadu District, Guangzhou, Guangdong Applicant after: GUANGDONG RUNHE BIOTECHNOLOGY CO., LTD. Applicant after: Guangdong Medical University Address before: 510800 13, Fengshang building, 10 Fenghuang North Road, Huadu District, Guangzhou, Guangdong Applicant before: GUANGDONG RUNHE BIOTECHNOLOGY CO., LTD. Applicant before: Guangdong Medical College |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170818 |